Verastem Oncology Boosts Ovarian Cancer Treatment with Positive Phase 2 RAMP-201 Trial Results
Verastem Oncology, a biopharmaceutical company developing cancer treatments, today reports positive interim data for avutometinib (VS-6766) from Part A of the ongoing RAMP 201 Phase 2 study evaluating ...